Zymeworks Inc. Common Stock ZYME
i
Market dataready · fetched 2026-11-11T15:57:43.985Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:57:35.535069285Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T15:57:43.142095+00:00
Zymeworks Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 20.63 | 388.5% | 39.2% | |||
| 25Δ | 21.91 | 369.9% | 36.6% | |||
| 30Δ | 23.19 | 351.3% | 34.1% | |||
| 35Δ | 24.47 | 332.6% | 31.5% | |||
| 40Δ | 25.75 | 314.0% | 28.9% | |||
| 45Δ | 27.03 | 295.4% | 26.3% | |||
| 50Δ | 29.68 | 85.9% | 5.9% | 28.32 | 276.7% | 23.7% |
| 55Δ | 28.98 | 91.1% | 5.3% | 29.60 | 258.1% | 21.1% |
| 60Δ | 28.28 | 96.3% | 4.7% | 30.88 | 239.5% | 18.5% |
| 65Δ | 27.58 | 101.4% | 4.1% | 32.16 | 220.8% | 16.0% |
| 70Δ | 26.88 | 106.6% | 3.5% | 33.44 | 202.2% | 13.4% |
| 75Δ | 26.18 | 111.8% | 2.9% | 34.73 | 183.6% | 10.8% |
| 80Δ | 25.48 | 117.0% | 2.3% | 36.01 | 164.9% | 8.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.63
- IV
- 388.5%
- B/E move
- 39.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.91
- IV
- 369.9%
- B/E move
- 36.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.19
- IV
- 351.3%
- B/E move
- 34.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.47
- IV
- 332.6%
- B/E move
- 31.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.75
- IV
- 314.0%
- B/E move
- 28.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.03
- IV
- 295.4%
- B/E move
- 26.3%
50Δ
- Pseudo strike
- 29.68
- IV
- 85.9%
- B/E move
- 5.9%
- Pseudo strike
- 28.32
- IV
- 276.7%
- B/E move
- 23.7%
55Δ
- Pseudo strike
- 28.98
- IV
- 91.1%
- B/E move
- 5.3%
- Pseudo strike
- 29.60
- IV
- 258.1%
- B/E move
- 21.1%
60Δ
- Pseudo strike
- 28.28
- IV
- 96.3%
- B/E move
- 4.7%
- Pseudo strike
- 30.88
- IV
- 239.5%
- B/E move
- 18.5%
65Δ
- Pseudo strike
- 27.58
- IV
- 101.4%
- B/E move
- 4.1%
- Pseudo strike
- 32.16
- IV
- 220.8%
- B/E move
- 16.0%
70Δ
- Pseudo strike
- 26.88
- IV
- 106.6%
- B/E move
- 3.5%
- Pseudo strike
- 33.44
- IV
- 202.2%
- B/E move
- 13.4%
75Δ
- Pseudo strike
- 26.18
- IV
- 111.8%
- B/E move
- 2.9%
- Pseudo strike
- 34.73
- IV
- 183.6%
- B/E move
- 10.8%
80Δ
- Pseudo strike
- 25.48
- IV
- 117.0%
- B/E move
- 2.3%
- Pseudo strike
- 36.01
- IV
- 164.9%
- B/E move
- 8.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 72.40% | |
| 70.28% | |
| 60.47% | |
| 56.54% | |
| 59.02% | |
| 57.02% | |
| 60.82% | |
| 66.23% | |
| 62.23% | |
| 64.20% |
Biotechnology
AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →ABSI
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid…
More →ABUS
Description unavailable
More →